GlassScriptPhysician profile
Ritesh Rathore
NPI 1467459263
$148,387.59
in general payments reported to CMS, 2019-2025
18 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $34K · 2021: $40K · 2022: $25K · 2023: $20K · 2024: $164 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Honoraria: $1,650 · Consulting Fee: $1,170 · Food and Beverage: $671 · Travel and Lodging: $636 · Education: $69.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,633.00 |
| Honoraria | $1,650.00 |
| Consulting Fee | $1,170.00 |
| Food and Beverage | $670.52 |
| Travel and Lodging | $636.08 |
| Education | $69.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105,245.09 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $22,460.42 | 2019-2022 | |
| Genzyme Corporation | $8,542.50 | 2020-2021 | |
| Glaxosmithkline, LLC. | $7,620.79 | 2020-2025 | Jemperli, Zejula |
| Deciphera Pharmaceuticals INC. | $2,411.08 | 2025 | Qinlock |
| Janssen Scientific Affairs, LLC | $1,170.00 | 2023 | Rybrevant |
| Celgene Corporation | $356.32 | 2022-2025 | Reblozyl |
| Kite Pharma, INC. | $120.00 | 2024 | Yescarta |
| Sanofi-Aventis U.S. LLC | $89.99 | 2021 | |
| Janssen Biotech, INC. | $72.71 | 2025 | Tecvayli, Darzalex |
| Epizyme, INC. | $64.99 | 2021 | |
| Exelixis INC. | $63.40 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $59.06 | 2025 | Keytruda, Keytruda Qlex, Prevymis |
| Janssen Pharmaceuticals, INC | $56.67 | 2022-2024 | Rybrevant |
| Astellas Pharma US INC | $24.88 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.07 | 2019 | |
| Puma Biotechnology, INC. | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritesh Rathore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.